Biostar Pharmaceuticals reported Q1 revenues climbed 9% to $7.4 million, while net income remained flat at $1.8 million. Earnings per share were 8 cents. The company said sales improved in four of its five SFDA approved drugs, a result of its initiative to market directly to rural consumers through retail pharmacies. The push to increase retail sales increased SG&A costs from 30% of revenues to 33%. That was enough to keep net income from rising in concert with total revenues. More details...

Stock Symbol: (OTCBB: BSPM)